Saturday - September 19, 2026
Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Improves Progression-Free Survival in HER2-Mutant NSCLC
September 14, 2026
BOSTON, Massachusetts, Sept. 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Improves Progression-Free Survival in HER2-Mutant NSCLC

*

A new study led by researchers at Dana-Farber Cancer Institute found that first-line trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembroliz . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products